查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
狂犬病免疫球蛋白市场 2022-2028
市场调查报告书
商品编码
1215774

狂犬病免疫球蛋白市场 2022-2028

Rabies Immunoglobulin Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3个工作天内

价格

在预测期内，全球狂犬病免疫球蛋白市场预计将以 6.1% 的复合年增长率显着增长。 预计在预测期内，增加 FDA 对主要参与者的批准将对市场产生积极支持。 例如，2021 年 6 月，基于 KEDRAB 在儿科人群中的安全性和有效性的新 FDA 批准在美国上市后临床试验中得到证明。 Kedrion Biopharma 和 Kamada Ltd. 是两家专注于血浆衍生蛋白疗法的领先生物製药公司，已获得 FDA 批准更新 KEDRAB（狂犬病免疫球蛋白（人））标籤，确认该产品在儿童中的安全性。并宣布它是有效的。

全球狂犬病免疫球蛋白市场根据类型进行细分。 根据类型，市场分为 HRIG 和 ERIG。 ERIG 是一种马 RIG，由马生产。 根据世界卫生组织 (WHO) 的说法，廉价且安全（纯化、经胃蛋白□消化的马血清）的马免疫球蛋白 (ERIG) 数量有限，而且在大多数情况下，最需要它的人无法获得。看来它是 因此，预测期内的市场增长将受到限制。 已经使用各种免疫原性製剂生产了各种类型的马抗狂犬病免疫球蛋白 (ERIG)，通常由狂犬病病毒的灭活和固定株组合组成。

从地域上看，全球狂犬病免疫球蛋白市场分为北美、欧洲、亚太地区和世界其他地区。 由于其发达的医疗基础设施和多家公司的存在，预计北美在预测期内将占据显着的市场份额。 该地区的人们对狂犬病有很好的了解，预计将在预测期内推动狂犬病免疫球蛋白市场。 根据疾病预防控制中心的数据，继两年零狂犬病病例后，2021 年美国将有 5 人死于狂犬病，这是一年中报告的狂犬病病例数最多的一年。 此外，美国的狂犬病死亡病例很少见，通常每年报告一到三例病例。

内容

第 1 章报告概述

  • 当前行业分析和增长前景
  • 研究方法和工具
  • 市场细分
    • 按细分
    • 按地区

第 2 章市场概述和洞察

  • 调查范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 推荐
    • 总结

第三章竞争格局

  • 主要公司分析
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期趋势
  • 关键策略分析

第四章市场细分

  • 全球狂犬病免疫球蛋白市场：按类型分类
    • 人狂犬病免疫球蛋白 (HRIG)
    • 马狂犬病免疫球蛋白 (ERIG)

第五章区域分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 其他亚太地区
  • 世界其他地方

第六章公司简介

  • Bharat Serums and Vaccines Ltd.（BSV）
  • CSL Behring
  • Grifols SA
  • Guangdong Shuanglin Bio-Pharmacy Co, Ltd.
  • Haffkine Bio-Pharmaceutical Corp. LTD.
  • Kamada Ltd.
  • Lanzhou Institute Of Biological Products Co., Ltd.
  • Premium Serums and Vaccines Pvt.Ltd.（PSVPL）
  • Sanofi SA
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shanghai Serum Bio-technology Co., LTD.
  • Shenzhen Weiguang Biological Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical CO., Ltd.
  • Sun Pharmaceuticals Co. Ltd.
  • VINS Bioproducts Ltd
Product Code: OMR2026830

Title:Global Rabies Immunoglobulin Market Size, Share & Trends Analysis Report by Type (Human Rabies Immune Globulin (HRIG) and Equine Rabies Immuno Globulin (ERIG)) Forecast Period (2022-2028).

The global rabies immunoglobulin market is anticipated to grow at a substantial CAGR of 6.1% during the forecast period. The increasing FDA approvals to key players are expected to support the market positively during the forecast period. For instance, in June 2021, new FDA Approval based on the safety and effectiveness of KEDRAB in the pediatric population was demonstrated in a US post-marketing clinical trial. Kedrion Biopharma and Kamada Ltd., are two key biopharmaceutical companies focused on plasma-derived protein therapeutics announced the FDA approved a label update for KEDRAB (Rabies Immune Globulin (Human)), establishing the product's safety and effectiveness in children.

The global rabies immunoglobulin market is segmented based on type. Based on the type, the market is segmented into HRIG and ERIG. ERIG is an equine RIG and is produced in horses. According to the World Health Organization (WHO), cheaper and safe (purified pepsin digested horse serum) equine immunoglobulin (ERIG) is available in limited quantities and most situations are inaccessible to those that need it most. Thus, limiting the market growth during the forecast period. Different types of equine antirabies immunoglobulin (ERIG) have been produced using various immunogenic preparations, consisting usually of a combination of inactivated and fixed strains of rabies virus.

Geographically, the global rabies immunoglobulin market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region is expected to hold a prominent share in the market during the forecast period due to the well-developed healthcare infrastructure and presence of several players in the region. The people in the region are well aware of rabies disease which is expected to propel the rabies immunoglobulin market during the forecast period. According to the CDC, five people died of rabies in the US in 2021, and following two years of zero rabies cases reported in the US and is the highest number reported per year. Further, rabies deaths in the U.S. are rare, with typically one to three cases reported annually.

The major companies serving the global rabies immunoglobulin market include Bharat Serums and Vaccines Ltd. (BSV), CSL Behring, Grifols SA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in December 2019, Kamada Ltd., a plasma-derived protein therapeutics company entered into a binding term sheet for a 12-year contract manufacturing agreement with an undisclosed partner to manufacture a US Food and Drug Administration (FDA) approved and commercialized specialty hyper-immune globulin product. Following the execution of the required technology transfer from the current manufacturer, and pending obtaining all required FDA approvals, Kamada is expected to commence commercial manufacturing of the product in early 2023.

Research Methodology

The market study of the global rabies immunoglobulin market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Rabies Immunoglobulin Market Research and Analysis by Type.

The Report Covers:

  • Comprehensive research methodology of the global rabies immunoglobulin market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global rabies immunoglobulin market.
  • Insights about market determinants that are stimulating the global rabies immunoglobulin market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Rabies Immunoglobulin Market by Type
    • 4.1.1. Human Rabies Immune Globulin (HRIG)
    • 4.1.2. Equine Rabies Immunoglobulin (ERIG)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bharat Serums and Vaccines Ltd. (BSV)
  • 6.2. CSL Behring
  • 6.3. Grifols SA
  • 6.4. Guangdong Shuanglin Bio-Pharmacy Co, Ltd.
  • 6.5. Haffkine Bio-Pharmaceutical Corp. LTD.
  • 6.6. Kamada Ltd.
  • 6.7. Lanzhou Institute Of Biological Products Co., Ltd.
  • 6.8. Premium Serums and Vaccines Pvt.Ltd. (PSVPL)
  • 6.9. Sanofi SA
  • 6.10. Shanghai RAAS Blood Products Co., Ltd.
  • 6.11. Shanghai Serum Bio-technology Co., LTD.
  • 6.12. Shenzhen Weiguang Biological Products Co., Ltd.
  • 6.13. Sichuan Yuanda Shuyang Pharmaceutical CO., Ltd.
  • 6.14. Sun Pharmaceuticals Co. Ltd.
  • 6.15. VINS Bioproducts Ltd

LIST OF TABLES

  • 1. GLOBAL RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL HUMAN RABIES IMMUNE GLOBULIN (HRIG) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL EQUINE RABIES IMMUNO GLOBULIN (ERIG) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. NORTH AMERICAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 6. NORTH AMERICAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 7. EUROPEAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 8. EUROPEAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 9. ASIA-PACIFIC RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 10. ASIA-PACIFIC RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 11. REST OF THE WORLD RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. REST OF THE WORLD RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RABIES IMMUNOGLOBULIN MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL HRIG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 3. GLOBAL ERIG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL RABIES IMMUNOGLOBULIN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. US RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 6. CANADA RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 7. UK RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 8. FRANCE RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 9. GERMANY RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 10. ITALY RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 11. SPAIN RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. REST OF EUROPE RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. INDIA RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. CHINA RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. JAPAN RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. REST OF THE WORLD RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)